This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing GH treatment for statural indications.

Inclusion Criteria:

• Bone age of at least 15 years for girls or at least 16 years for boys within 6 months of obtaining the DXA scan
• Previous enrollment in the NCGS core study, 85-036
• Tanner Stage 4 or greater
• Either spontaneous or induced puberty
• Subjects who plan on terminating GH treatment for statural purposes for one or more of the following reasons: epiphyseal fusion, slowing growth rate indicates that near adult height has been reached, or satisfied with current height

Exclusion Criteria:

• Current therapy with a non Genentech GH product
• Pregnancy (to avoid exposure to low levels of radiation from DXA scanners)
• Bilateral hip replacement
• Weight >130 kg (286 lb.)

primary care clinic